Moderna Inc.’s MRNA stock has surged approximately 37% in the last month but has dipped around 15% year to date.On Wednesday, the stock is trading around 7% higher.Notably, there is no news to justify the movement. Over the last month:The U.S. Food and Drug Administration (FDA) approved Moderna’s supplemental Biologics License Application (sBLA) for Spikevax, the company's COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.Moderna revealed results ...